Xywav
Combination drug
From Wikipedia, the free encyclopedia
Xywav (calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate) is a fixed-dose combination medication used to treat cataplexy or excessive daytime sleepiness.[1][2] It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate.[1] It is a central nervous system (CNS) depressant and it is taken by mouth.[1]
| Combination of | |
|---|---|
| Calcium oxybate | Central nervous system depressant |
| Magnesium oxybate | Central nervous system depressant |
| Potassium oxybate | Central nervous system depressant |
| Sodium oxybate | Central nervous system depressant |
| Clinical data | |
| Trade names | Xywav |
| Other names | JZP-258 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a621001 |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
It is manufactured by Jazz Pharmaceuticals and was approved for medical use in the United States in July 2020.[1][3]
Medical uses
Xywav is indicated for the treatment of cataplexy or excessive daytime sleepiness in people aged seven years of age and older with narcolepsy;[1][4] and for idiopathic hypersomnia.[4][5]
Xywav is recommended to be dosed twice nightly in narcolepsy and idiopathic hypersomnia (≤9g total),[6] with an additional option for once nightly dosing in idiopathic hypersomnia (≤6g).[7]
Research
In September 2025, Jazz Pharmaceuticals presented data from an open-label study evaluating higher doses of Xywav in narcoleptic patients; the analysis reported that doses of 9-12 g nightly were associated with additional improvements in excessive daytime sleepiness and cataplexy frequency compared with the currently approved maximum dose of ≤9 g.[8]
Chemical composition
Side effects
The US Food and Drug Administration label for Xywav contains a boxed warning for central nervous system depression, abuse, and misuse.[1]
Respiratory
Slowed breathing, trouble breathing, sleep apnea.[1]
Psychiatric
Confusion, hallucination, unusual or disturbing thoughts (abnormal thinking), anxiety, depression, suicidal thoughts or actions, increased tiredness, feelings of guilt or worthlessness, and difficulty concentrating.[1]
Other
Society and culture
Legal status
Xywav was granted orphan drug designation by the US Food and Drug Administration.[4][9]
Xywav is a prescription drug and a Schedule III controlled substance in the United States.[1]
Other names
In the testing phase of the drug, it was known as JZP-258.[10]
Calcium, magnesium, potassium, and sodium oxybate are salts of gamma hydroxybutyrate (GHB).[11][12]
